Table 11:

Study Characteristics of Ranibizumab Versus Aflibercept RCTs for n-AMD

Study, Author, Year, Country	Study Design and Follow-Up	Sites, Patients (P)	Trial Arms	Follow-Up Investigations
VIEW 1, Heir et al, 2012, (68) United States and Canada	4-arm, double-masked multinational, parallel-group active control non-inferiority RCT 1 year	154 sites, 1,217 Ps	Randomization to monthly 0.5 mg of aflibercept, monthly 2.0 mg of aflibercept, or 2 mg of aflibercept every 2 months or 0.5 mg of ranibizumab monthly	Monthly visits including VA, anterior/posterior exam with IOP. Fundus photography and FA at baseline and at weeks 24 and 52, and OCT at baseline and at weeks 4, 12, 24, 36, and 52 and optional between scheduled dates
VIEW 2, Heir et al, 2012, (68) Europe, Middle East, Asia-Pacific, and Latin America	4-arm, double-masked multinational, parallel-group active control non-inferiority RCT 1 year	172 sites, 1,240 Ps	Randomization to monthly 0.5 mg of aflibercept, monthly 2.0 mg of aflibercept or 2 mg of aflibercept every 2 months, or 0.5 mg of ranibizumab monthly	Monthly visits including VA, anterior/posterior exam with IOP. fundus photography and FA at baseline, weeks 24 and 52, and OCT at baseline and weekly afterward

Abbreviations: FA, fluorescein angiography; IOP, intraocular pressure; OCT, optical coherence tomography; P, Patient; RCT, randomized controlled trial; VA, visual acuity.